The content on this site is intended for healthcare professionals only
Dr Nelson talks to ecancertv at ASCO GU 2014.
Targeting the androgen receptor pathway to tackle prostate cancer has been a staple of treatment for decades; Dr Nelson looks at the biological basis behind this, with a view to new and future agents.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
Latest in PARP inhibitors and combination therapies for prostate cancer
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma
